For children with type 1 diabetes, managing blood sugar is a lifelong challenge, but a newly approved treatment offers hope of preserving their body’s ability to produce insulin.

Industry observers note that for children newly diagnosed with type 1 diabetes, insulin is essential for controlling blood sugar, but it cannot stop the immune system from destroying the cells that produce it. A newly approved treatment offers a way to slow that damage and preserve more of the body’s own insulin production. However, families have only a short window after diagnosis to consider the option.

Sources indicate that in June 2026, the U.S. Food and Drug Administration (FDA) expanded its approval of teplizumab to include children and adolescents ages 8 to 17 with newly diagnosed stage 3 type 1 diabetes. This is the stage when symptoms appear and insulin treatment becomes necessary. The expansion was granted through the FDA’s accelerated approval pathway, based on evidence that the drug helps preserve insulin production. Teplizumab was already approved for people ages 1 and older with stage 2 type 1 diabetes to delay progression to stage 3.

Recent findings suggest that type 1 diabetes develops when the immune system attacks beta cells in the pancreas, which produce insulin to help the body use energy from food and regulate blood sugar. Some of these cells usually remain when symptoms first appear. Teplizumab targets the immune cells responsible for the damage, potentially extending the “honeymoon” period when patients still produce some insulin themselves.

Industry observers note that “Insulin is essential in stage 3 type 1 diabetes, but it doesn’t address the immune process that is destroying the cells that make insulin,” said Kimber Simmons, MD, MS, an associate professor of pediatrics at the University of Colorado Anschutz School of Medicine and a physician-scientist at the Barbara Davis Center for Diabetes. “Teplizumab gives us an opportunity to preserve some of the beta cells and insulin-producing capacity that a person still has. The goal is to intervene early enough to make a meaningful difference.”.

Recent findings suggest that evidence supporting the expanded approval came from the PROTECT clinical trial, which involved 328 children and adolescents. After 78 weeks, participants who received teplizumab retained significantly more insulin-producing capacity than those given a placebo. Researchers measured this using C-peptide, a marker of how much insulin the body produces naturally.

In a recent development, nearly 95% of children treated with teplizumab maintained a clinically meaningful level of their own insulin production, compared with about 79% of those receiving placebo. Separate studies involving people with type 1 diabetes have linked higher C-peptide levels with fewer episodes of severe low blood sugar, reduced insulin requirements, and a lower risk of certain complications, including diabetic eye disease.

The timing of treatment is particularly vital. Teplizumab must be started within eight weeks of diagnosis, while participants in PROTECT began treatment within six weeks. Earlier research also suggested that starting treatment sooner may produce stronger responses.

It has been revealed that treatment involves two 12-day courses of daily intravenous infusions, typically six months apart. Potential side effects include rash, headache, nausea, and temporary reductions in lymphocytes, a type of white blood cell. More serious risks include cytokine release syndrome, an inflammatory reaction, infections, and viral reactivation. Experienced medical teams and careful monitoring are therefore necessary.

It has been revealed that teplizumab does not cure type 1 diabetes or eliminate the need for insulin. Instead, it introduces another way to manage the disease by addressing the underlying immune process.

According to recent reports, to help clinicians and families navigate these decisions, Simmons led a national group of clinical trial investigators and pediatric diabetes specialists in developing practical guidance published in Diabetes Care. Supported by Breakthrough T1D, the guidance combines clinical trial evidence with experience in everyday patient care. It covers patient selection, potential benefits and risks, shared decision-making, safety monitoring, and treatment planning.

Simmons, who also practices at Children’s Hospital Colorado, co-authored the published results of both PROTECT and PETITE-T1D, a study examining teplizumab in children younger than 8 with stage 2 type 1 diabetes.

“Once a treatment is approved, the question becomes: How do we actually do this in the clinic?” mentioned Simmons. “The way patients are treated in the real world doesn’t always line up perfectly with a clinical trial protocol. We wanted to give clinicians practical guidance so they can have informed conversations with families and make thoughtful, safe decisions.”.

The guidance also addresses a longstanding challenge in medicine: translating research advances into routine care.

“Research demonstrates that, on average, it takes 17 years for landmark medical breakthroughs to become widely adopted in routine clinical practice. Closing that gap is essential to getting the best science to people sooner,” remarked Breakthrough T1D Senior Vice President of Medical Affairs Anastasia Albanese-O’Neill, Ph.D., APRN, CDCES. “Breakthrough T1D is focused on efforts that will close this gap in a way that is safe and supports shared decision-making between clinicians and families. This new clinical guidance serves as an important tool that will help guide timely care for children with a new stage 3 type 1 diabetes diagnosis. We’re grateful to the leaders who provided their expertise and time to develop it.”.

The authors emphasize that teplizumab should be incorporated into existing diabetes care rather than delivered through an entirely separate treatment system.

“We don’t want to create a separate pathway that fragments care,” stated Simmons. “This is an opportunity to be thoughtful about how we use a newly introduced therapy while keeping the whole patient in view. Our specialty needs to stay focused on providing the best coordinated care we can.”.

Reference: “Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With Upcoming-Onset (Stage 3) Type 1 Diabetes” by Kimber M. Simmons, Adriana Weinberg, Emily Breidbart, Carla Demeterco-Berggren, Stephen Gitelman, Kevan C. Herold, Shideh Majidi, Daniel Moore, Amara Ogbonnaya-Whittlesey, Neha Patel, Jennifer L. Sherr, Emily K. Sims, Kupper Wintergerst and Michael J. Haller, 11 November 2026, Diabetes Care. DOI: 10.2337/dci26-0061.

Never miss a breakthrough: Join the SciTechDaily newsletter.Follow us on Google and Google News.

→ Read original article